ArticleJournal of thoracic disease2025
Combination of radiotherapy and immunochemotherapy improves survival outcomes in non-small cell lung cancer patients with liver metastasis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) with liver metastasis carries a poor prognosis, and evidence for optimal treatment strategies remains limited. The combination of radiotherapy (RT) and immunochemotherapy has shown promise in improving survival outcomes for patients with advanced NSCLC, however, large cohort studies targeting NSCLC with liver metastasis are lacking. The purpose of this study was to analyze the impact of RT combined with immunochemotherapy on the long-term survival of NSCLC patients with liver metastasis leveraging data from the Surveillance, Epidemiology, and End Results Program (SEER) database and Xinqiao Hospital in China. Methods: Patients diagnosed with NSCLC and liver metastasis between 2010 and 2020 were screened from the SEER 17 registry. Patients were categorized into three cohorts: immunochemotherapy alone (IOC), RT + immunochemotherapy (RT + IOC) and chemotherapy + RT (CRT). Survival analysis, propensity score matching (PSM), subgroup analysis, and Cox regression were performed. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS). Additionally, data from Xinqiao Hospital were used for validation. Results: A total of 6,309 patients were enrolled, including 1,691 in the IOC cohort, 1,605 in the RT + IOC cohort, and 3,013 in the CRT cohort. The median overall survival (mOS) was significantly higher in the RT + IOC cohort compared to the IOC cohort (9 Conclusions: The combination of radiotherapy and immunochemotherapy provides better survival benefits for NSCLC patients with liver metastasis than immunochemotherapy alone or chemotherapy + radiotherapy. Further research is necessary to explore the optimal radiotherapy methods for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.